Plain-English translation of NCT05956418 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing a new medication called to see if it can help patients who are in hypovolemic shock — a life-threatening condition where severe bleeding or fluid loss causes dangerously low blood pressure. You would receive this medication as an IV infusion along with all the standard emergency treatments your doctors would normally give you, such as fluids, blood pressure support, and breathing assistance.
Hypovolemic shock is a medical emergency with high death rates, and doctors need better ways to help patients survive alongside standard treatments. This trial is testing whether this medication can improve blood pressure faster, reduce dangerous chemicals that build up in the blood, and ultimately save more lives.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the new medication as an IV infusion over one hour, mixed with saline. Depending on your blood pressure response, you may receive up to three doses per day for up to two days. Throughout your hospital stay and for up to seven days after enrollment, your doctors will closely monitor your blood pressure, blood tests, and overall recovery. You'll be watched until you leave the hospital or day 7, whichever comes first.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
India